Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort
expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor
agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumours or tumor types with
high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with
solid tumour and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a
phase I-IIa clinical trial
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Maastricht University
Collaborators:
Academisch Ziekenhuis Maastricht Erasmus Medical Center Jules Bordet Institute The Netherlands Cancer Institute